Expleo Solutions Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 18, 2025, 11:16 am

Competitors of Expleo Solutions Ltd

All Competitor Stocks of Expleo Solutions Ltd

Quarterly Result

Last Updated: August 20, 2025, 11:00 am

Below is a detailed analysis of the quarterly data for Expleo Solutions Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 260.00 Cr.. The value appears strong and on an upward trend. It has increased from 256.00 Cr. (Mar 2025) to 260.00 Cr., marking an increase of 4.00 Cr..
• For Expenses, as of Jun 2025, the value is 230.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 216.00 Cr. (Mar 2025) to 230.00 Cr., marking an increase of 14.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 30.00 Cr.. The value appears to be declining and may need further review. It has decreased from 40.00 Cr. (Mar 2025) to 30.00 Cr., marking a decrease of 10.00 Cr..
• For OPM %, as of Jun 2025, the value is 11.00%. The value appears to be declining and may need further review. It has decreased from 16.00% (Mar 2025) to 11.00%, marking a decrease of 5.00%.
• For Other Income, as of Jun 2025, the value is 7.00 Cr.. The value appears strong and on an upward trend. It has increased from 5.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 2.00 Cr..
• For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 8.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 36.00 Cr. (Mar 2025) to 28.00 Cr., marking a decrease of 8.00 Cr..
• For Tax %, as of Jun 2025, the value is 28.00%. The value appears to be improving (decreasing) as expected. It has decreased from 32.00% (Mar 2025) to 28.00%, marking a decrease of 4.00%.
• For Net Profit, as of Jun 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 24.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 4.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 13.16. The value appears to be declining and may need further review. It has decreased from 15.52 (Mar 2025) to 13.16, marking a decrease of 2.36.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 5:25 am

Growth

Last Updated: September 5, 2025, 3:50 am

Balance Sheet

Last Updated: June 16, 2025, 12:10 pm

Below is a detailed analysis of the balance sheet data for Expleo Solutions Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 16.00 Cr..
• For Reserves, as of Mar 2025, the value is 620.00 Cr.. The value appears strong and on an upward trend. It has increased from 596.00 Cr. (Mar 2024) to 620.00 Cr., marking an increase of 24.00 Cr..
• For Borrowings, as of Mar 2025, the value is 30.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 26.00 Cr. (Mar 2024) to 30.00 Cr., marking an increase of 4.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 165.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 128.00 Cr. (Mar 2024) to 165.00 Cr., marking an increase of 37.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 831.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 765.00 Cr. (Mar 2024) to 831.00 Cr., marking an increase of 66.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 113.00 Cr.. The value appears to be declining and may need further review. It has decreased from 131.00 Cr. (Mar 2024) to 113.00 Cr., marking a decrease of 18.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 5.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 15.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 15.00 Cr..
• For Other Assets, as of Mar 2025, the value is 719.00 Cr.. The value appears strong and on an upward trend. It has increased from 614.00 Cr. (Mar 2024) to 719.00 Cr., marking an increase of 105.00 Cr..
• For Total Assets, as of Mar 2025, the value is 831.00 Cr.. The value appears strong and on an upward trend. It has increased from 765.00 Cr. (Mar 2024) to 831.00 Cr., marking an increase of 66.00 Cr..

Notably, the Reserves (620.00 Cr.) exceed the Borrowings (30.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Expleo Solutions Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 66.52. This value is within the healthy range. It has increased from 58.27 (Mar 24) to 66.52, marking an increase of 8.25.
• For Diluted EPS (Rs.), as of Mar 25, the value is 66.52. This value is within the healthy range. It has increased from 58.27 (Mar 24) to 66.52, marking an increase of 8.25.
• For Cash EPS (Rs.), as of Mar 25, the value is 91.85. This value is within the healthy range. It has increased from 79.96 (Mar 24) to 91.85, marking an increase of 11.89.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 409.69. It has increased from 393.78 (Mar 24) to 409.69, marking an increase of 15.91.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 409.69. It has increased from 393.78 (Mar 24) to 409.69, marking an increase of 15.91.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 660.31. It has increased from 621.69 (Mar 24) to 660.31, marking an increase of 38.62.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 117.18. This value is within the healthy range. It has increased from 100.42 (Mar 24) to 117.18, marking an increase of 16.76.
• For PBIT / Share (Rs.), as of Mar 25, the value is 91.86. This value is within the healthy range. It has increased from 78.73 (Mar 24) to 91.86, marking an increase of 13.13.
• For PBT / Share (Rs.), as of Mar 25, the value is 89.72. This value is within the healthy range. It has increased from 77.05 (Mar 24) to 89.72, marking an increase of 12.67.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 66.52. This value is within the healthy range. It has increased from 58.27 (Mar 24) to 66.52, marking an increase of 8.25.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 66.52. This value is within the healthy range. It has increased from 58.27 (Mar 24) to 66.52, marking an increase of 8.25.
• For PBDIT Margin (%), as of Mar 25, the value is 17.74. This value is within the healthy range. It has increased from 16.15 (Mar 24) to 17.74, marking an increase of 1.59.
• For PBIT Margin (%), as of Mar 25, the value is 13.91. This value is within the healthy range. It has increased from 12.66 (Mar 24) to 13.91, marking an increase of 1.25.
• For PBT Margin (%), as of Mar 25, the value is 13.58. This value is within the healthy range. It has increased from 12.39 (Mar 24) to 13.58, marking an increase of 1.19.
• For Net Profit Margin (%), as of Mar 25, the value is 10.07. This value exceeds the healthy maximum of 10. It has increased from 9.37 (Mar 24) to 10.07, marking an increase of 0.70.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.07. This value is within the healthy range. It has increased from 9.37 (Mar 24) to 10.07, marking an increase of 0.70.
• For Return on Networth / Equity (%), as of Mar 25, the value is 16.23. This value is within the healthy range. It has increased from 14.79 (Mar 24) to 16.23, marking an increase of 1.44.
• For Return on Capital Employeed (%), as of Mar 25, the value is 20.76. This value is within the healthy range. It has increased from 18.48 (Mar 24) to 20.76, marking an increase of 2.28.
• For Return On Assets (%), as of Mar 25, the value is 12.42. This value is within the healthy range. It has increased from 11.82 (Mar 24) to 12.42, marking an increase of 0.60.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.28. It has decreased from 1.29 (Mar 24) to 1.28, marking a decrease of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 3.90. This value exceeds the healthy maximum of 3. It has decreased from 5.77 (Mar 24) to 3.90, marking a decrease of 1.87.
• For Quick Ratio (X), as of Mar 25, the value is 3.90. This value exceeds the healthy maximum of 2. It has decreased from 5.77 (Mar 24) to 3.90, marking a decrease of 1.87.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 75.16. This value exceeds the healthy maximum of 50. It has increased from 8.58 (Mar 24) to 75.16, marking an increase of 66.58.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 54.43. This value exceeds the healthy maximum of 50. It has increased from 6.25 (Mar 24) to 54.43, marking an increase of 48.18.
• For Earning Retention Ratio (%), as of Mar 25, the value is 24.84. This value is below the healthy minimum of 40. It has decreased from 91.42 (Mar 24) to 24.84, marking a decrease of 66.58.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 45.57. This value is within the healthy range. It has decreased from 93.75 (Mar 24) to 45.57, marking a decrease of 48.18.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 54.75. This value is within the healthy range. It has decreased from 59.74 (Mar 24) to 54.75, marking a decrease of 4.99.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 32.08. This value is within the healthy range. It has decreased from 35.66 (Mar 24) to 32.08, marking a decrease of 3.58.
• For Enterprise Value (Cr.), as of Mar 25, the value is 1,006.97. It has decreased from 1,697.97 (Mar 24) to 1,006.97, marking a decrease of 691.00.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 1. It has decreased from 1.76 (Mar 24) to 0.98, marking a decrease of 0.78.
• For EV / EBITDA (X), as of Mar 25, the value is 5.54. This value is within the healthy range. It has decreased from 10.89 (Mar 24) to 5.54, marking a decrease of 5.35.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.21. This value is within the healthy range. It has decreased from 1.95 (Mar 24) to 1.21, marking a decrease of 0.74.
• For Retention Ratios (%), as of Mar 25, the value is 24.83. This value is below the healthy minimum of 30. It has decreased from 91.41 (Mar 24) to 24.83, marking a decrease of 66.58.
• For Price / BV (X), as of Mar 25, the value is 1.94. This value is within the healthy range. It has decreased from 3.08 (Mar 24) to 1.94, marking a decrease of 1.14.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.21. This value is within the healthy range. It has decreased from 1.95 (Mar 24) to 1.21, marking a decrease of 0.74.
• For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.08, marking an increase of 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness